Merck snags rights to NanoBio's adjuvant vaccine tech

After collaborating with the University of Michigan-spinout NanoBio over the past three years, Merck ($MRK) has signed off on a new licensing pact for the biotech's nanoemulsion adjuvant technology. NanoBio has been doing some studies on the new technology's ability to spur a strong immune response when used intranasally. The pharma giant gets exclusive rights to use it for an RSV vaccine and non-exclusive rights for use in an intranasal as well as a universal flu vaccine. NanoBio scored an upfront and milestones in the deal, but didn't disclose the terms. Release